

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sunitinib

INITIATION – RCC

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has metastatic renal cell carcinoma
and
☐ The patient has not previously received funded sunitinib

CONTINUATION – RCC

Re-assessment required after 4 months

Prerequisites (tick box where appropriate)

- ☐ No evidence of disease progression

INITIATION – GIST

Re-assessment required after 3 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST)
and
☐ The patient's disease has progressed following treatment with imatinib
or
☐ The patient has documented treatment-limiting intolerance, or toxicity to, imatinib

CONTINUATION – GIST

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- ☐ The patient has had a complete response (disappearance of all lesions and no new lesions)
or
☐ The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease)
or
☐ The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression

- and**
☐ The treatment remains appropriate and the patient is benefiting from treatment

CONTINUATION – GIST pandemic circumstances

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST)
and
☐ The patient is clinically benefiting from treatment and continued treatment remains appropriate
and
☐ Sunitinib is to be discontinued at progression
and
☐ The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Sunitinib - *continued*

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

I confirm that the above details are correct:

Signed: Date: